We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

When bad is good

7 December 2006 By Robert Cyran

There are now only six US companies with a tripleA ratings left. And Pfizer s is under review for a possible downgrade. The number has fallen nearly 90% over 25 years. While smart financing explains some of the trend, there are other less brilliant reasons.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)